Nuveen
TARS icon

Nuveen’s Tarsus Pharmaceuticals TARS Stock Holding History

Nuveen’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.09M Sell
96,819
-218,471
-69% -$14M ﹤0.01% 1986
2026
Q1 		$22.1M Sell
315,290
-7,237
-2% -$506K 0.01% 1072
2025
Q4 		$26.4M Sell
322,527
-8,153
-2% -$609K 0.01% 979
2025
Q3 		$19.7M Sell
330,680
-6,259
-2% -$308K 0.01% 1161
2025
Q2 		$13.6M Buy
336,939
+72,416
+27% +$3.26M ﹤0.01% 1318
2025
Q1 		$13.6M Buy
264,523
+138,984
+111% +$6.87M ﹤0.01% 1367
2024
Q4 		$6.95M Sell
125,539
-15,186
-11% -$690K ﹤0.01% 1807
2024
Q3 		$4.63M Sell
140,725
-244,360
-63% -$6.87M ﹤0.01% 2026
2024
Q2 		$10.5M Buy
385,085
+228,298
+146% +$7.68M ﹤0.01% 1552
2024
Q1 		$5.7M Sell
156,787
-79,655
-34% -$2.34M ﹤0.01% 1922
2023
Q4 		$4.79M Buy
236,442
+130,841
+124% +$2.18M ﹤0.01% 2006
2023
Q3 		$1.88M Buy
105,601
+36,139
+52% +$640K ﹤0.01% 2323
2023
Q2 		$1.26M Buy
69,462
+25,582
+58% +$407K ﹤0.01% 2556
2023
Q1 		$552K Sell
43,880
-5,185
-11% -$75.8K ﹤0.01% 2788
2022
Q4 		$719K Sell
49,065
-7,953
-14% -$132K ﹤0.01% 2800
2022
Q3 		$976K Sell
57,018
-2,052
-3% -$32.6K ﹤0.01% 2765
2022
Q2 		$862K Buy
59,070
+37,307
+171% +$560K ﹤0.01% 2854
2022
Q1 		$381K Hold
21,763
– – ﹤0.01% 3076
2021
Q4 		$565K Hold
21,763
– – ﹤0.01% 3045
2021
Q3 		$496K Sell
21,763
-3,960
-15% -$98K ﹤0.01% 3168
2021
Q2 		$745K Buy
25,723
+10,891
+73% +$340K ﹤0.01% 3099
2021
Q1 		$478K Buy
14,832
+4,744
+47% +$175K ﹤0.01% 3106
2020
Q4 		$417K Buy
+10,088
New +$287K ﹤0.01% 3079

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Nuveen's TARS Position: Q2 2026 in Review

Nuveen reduced its Tarsus Pharmaceuticals (TARS) stake by 69% in Q2 2026, selling an estimated $14M and leaving 96,819 shares worth $6.09M. The position accounts for ﹤0.01% of the portfolio, ranked #1986.

Nuveen first reported a position in TARS in Q4 2020 and has held it in 23 quarters since. The position peaked at $26.4M in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Nuveen held 96,819 shares of Tarsus Pharmaceuticals worth $6.09M as of Q2 2026.
  • Nuveen sold 218,471 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $14M.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1986 holding.
  • Nuveen first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Nuveen's Tarsus Pharmaceuticals position peaked at $26.4M in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.